Table 2 The cumulative incidences of severity of hearing loss by type of aminoglycoside in the MDR-TB drug regimen
Severity of hearing loss | Amikacin group (n = 51) | Cumulative incidence | Kanamycin group (n = 302) | Cumulative incidence | Total cases (N = 353) | Cumulative incidence |
|---|---|---|---|---|---|---|
Mild | 5 | 10Â % | 60 | 20Â % | 65 | 18Â % |
Moderate | 7 | 14Â % | 41 | 14Â % | 48 | 14Â % |
Moderate-Severe | 6 | 12Â % | 27 | 9Â % | 33 | 9Â % |
Severe | 5 | 10Â % | 16 | 5Â % | 21 | 6Â % |
Profound | 11 | 22Â % | 21 | 7Â % | 32 | 9Â % |
Missing severity grading | 4 | 8Â % | 3 | 1Â % | 7 | 2Â % |
Total cases | 38 | 75Â % | 168 | 56Â % | 206 | 58Â % |